These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28074573)

  • 1. Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.
    Pannone L; Bocchinfuso G; Flex E; Rossi C; Baldassarre G; Lissewski C; Pantaleoni F; Consoli F; Lepri F; Magliozzi M; Anselmi M; Delle Vigne S; Sorge G; Karaer K; Cuturilo G; Sartorio A; Tinschert S; Accadia M; Digilio MC; Zampino G; De Luca A; Cavé H; Zenker M; Gelb BD; Dallapiccola B; Stella L; Ferrero GB; Martinelli S; Tartaglia M
    Hum Mutat; 2017 Apr; 38(4):451-459. PubMed ID: 28074573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
    Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
    J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic PTPN11 variants involving the poly-glutamine Gln
    Martinelli S; Pannone L; Lissewski C; Brinkmann J; Flex E; Schanze D; Calligari P; Anselmi M; Pantaleoni F; Canale VC; Radio FC; Ioannides A; Rahner N; Schanze I; Josifova D; Bocchinfuso G; Ryten M; Stella L; Tartaglia M; Zenker M
    Hum Mutat; 2020 Jun; 41(6):1171-1182. PubMed ID: 32112654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
    Tartaglia M; Kalidas K; Shaw A; Song X; Musat DL; van der Burgt I; Brunner HG; Bertola DR; Crosby A; Ion A; Kucherlapati RS; Jeffery S; Patton MA; Gelb BD
    Am J Hum Genet; 2002 Jun; 70(6):1555-63. PubMed ID: 11992261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHP2 sails from physiology to pathology.
    Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
    Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
    Martinelli S; Torreri P; Tinti M; Stella L; Bocchinfuso G; Flex E; Grottesi A; Ceccarini M; Palleschi A; Cesareni G; Castagnoli L; Petrucci TC; Gelb BD; Tartaglia M
    Hum Mol Genet; 2008 Jul; 17(13):2018-29. PubMed ID: 18372317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
    Lorca R; Pannone L; Cuesta-Llavona E; Bocchinfuso G; Rodríguez-Reguero J; Carpentieri G; Hernando I; Flex E; Tartaglia M; Coto E; Gómez J; Martinelli S
    Clin Genet; 2021 Mar; 99(3):457-461. PubMed ID: 33354767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the Molecular Basis of the Noonan Syndrome-Causing Mutation T42A of SHP2.
    Toto A; Malagrinò F; Visconti L; Troilo F; Gianni S
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
    Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
    J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
    Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
    Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the PTPN11 gene in Egyptian patients with Noonan syndrome.
    Essawi ML; Ismail MF; Afifi HH; Kobesiy MM; El Kotoury A; Barakat MM
    J Formos Med Assoc; 2013 Nov; 112(11):707-12. PubMed ID: 24183200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
    Tartaglia M; Mehler EL; Goldberg R; Zampino G; Brunner HG; Kremer H; van der Burgt I; Crosby AH; Ion A; Jeffery S; Kalidas K; Patton MA; Kucherlapati RS; Gelb BD
    Nat Genet; 2001 Dec; 29(4):465-8. PubMed ID: 11704759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.
    Carapito R; Paul N; Untrau M; Ott L; Corradini N; Poignant S; Geffroy L; Caldagues E; Heymann MF; Cassagnau E; Isidor B; Bahram S
    J Hum Genet; 2014 Jan; 59(1):57-9. PubMed ID: 24225993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
    Mutesa L; Pierquin G; Janin N; Segers K; Thomée C; Provenzi M; Bours V
    Cancer Genet Cytogenet; 2008 Apr; 182(1):40-2. PubMed ID: 18328949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
    Niihori T; Aoki Y; Ohashi H; Kurosawa K; Kondoh T; Ishikiriyama S; Kawame H; Kamasaki H; Yamanaka T; Takada F; Nishio K; Sakurai M; Tamai H; Nagashima T; Suzuki Y; Kure S; Fujii K; Imaizumi M; Matsubara Y
    J Hum Genet; 2005; 50(4):192-202. PubMed ID: 15834506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics and variation in phenotype in Noonan syndrome.
    Jongmans M; Otten B; Noordam K; van der Burgt I
    Horm Res; 2004; 62 Suppl 3():56-9. PubMed ID: 15539800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.